Magle Chemoswed Holding AB

MAGLE

SE0014401014

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 13:36:36 28/05/2024 BST			5-day change	1st Jan Change
33.4 ^SEK	+0.60%		+0.60%	+32.54%

04-18	Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-22	Magle Chemoswed Holding AB Resolves to Withdraws Dividend Proposal for the Year 2023	CI

Magle Chemoswed Holding AB Elects Martin Lidgard as New Member of Board

December 14, 2021 at 09:45 am

Magle Chemoswed Holding AB at its extraordinary general meeting held on December 14, 2021, elected Martin Lidgard as new member of the board until the end of general meeting 2022.

Latest news about Magle Chemoswed Holding AB

Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-18	CI
Magle Chemoswed Holding AB Resolves to Withdraws Dividend Proposal for the Year 2023	03-22	CI
Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.	03-21	CI
Magle Chemoswed Holding AB Proposes Dividend for the Fiscal Year 2023	02-16	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-16	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-16	CI
Magle Group Enters Collaboration with Sirtex Medical to Support the International Commercialization of Embocept S Dsm 50 Um	08/09/23	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/07/23	CI
Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023	29/04/23	CI
Magle Group Announces Positive Results from Post-Market Clinical Follow-Up of SmartPAN	27/04/23	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	16/02/23	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	16/02/23	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022	16/02/23	CI
Magle Chemoswed Holding AB 's Proprietary Product Axxo® Woundgel Receives Regulatory Approval in Kuwait	21/11/22	CI
Magle Group's Vascular Embolic Product Embocept® S Receives Regulatory Approval in Argentina	17/11/22	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	29/10/22	CI
Magle Appoints New Chief Marketing/Innovation Officer	12/09/22	MT
Magle Group Appoints Helena Ossmer Thedius as New Chief Marketing and Innovation Officer	12/09/22	CI
Magle Chemoswed Holding AB Announces the Resignation of Julia Kamber Rouhi from the Board of Directors of Magle Chemoswed Holding	16/08/22	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	29/07/22	CI
Magle Group Announces First Patients Enrolled in a Post-Market Study of Medical Device SmartPAN®	11/07/22	CI
Magle Chemoswed Holding AB Announces Post Market Clinical Study for SmartPAN®	13/05/22	CI
Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2022	29/04/22	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Full Year Ended December 31, 2021	25/02/22	CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	25/02/22	CI

Chart Magle Chemoswed Holding AB

Duration

Period

More charts

Magle Chemoswed Holding AB is a Sweden-based company that conducts research, development and manufacturing in the fields of pharmaceutical chemistry and pharmaceutical technology. The Company's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.

Sector

Pharmaceuticals

Calendar

17/07/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Magle Chemoswed Holding AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MAGLE CHEMOSWED HOLDING AB	+32.54%	34.21M
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	347B
MERCK & CO., INC.	+15.66%	319B
ABBVIE INC.	+0.24%	274B
ASTRAZENECA PLC	+13.47%	238B
NOVARTIS AG	+7.35%	204B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	161B
PFIZER, INC.	-1.70%	160B

Other Pharmaceuticals